ArticleAnnals of translational medicine2022

Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.

Meirong Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.